At WIRED Health, pioneering Alzheimer's researcher John Hardy outlined the stakes—and next steps—of where treatment is headed ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

US FDA approves Axsome Therapeutics’ Auvelity to treat agitation associated with dementia due to Alzheimer’s disease: New York Monday, May 4, 2026, 12:30 Hrs [IST] Axsome Ther ...

Auvelity targets the NMDA and sigma-1 receptors, providing the first non-antipsychotic treatment option for Alzheimer’s patients with agitation.

A single-cell platform reveals that many genetic mutations converge on shared cellular programs, pointing to simpler, more ...

FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...

Gates is a supporter of Alzheimer’s research, but scammers are using his name and likeness to promote fraudulent “cures” for the disease.

The FDA approves Alzheimer agitation treatment Auvelity, the first non-antipsychotic option for dementia-related agitation in adults.

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of ...

Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease May 1, 2026 8:00 ...